Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients
Status:
Completed
Trial end date:
2018-04-03
Target enrollment:
Participant gender:
Summary
In this study it was the rationale to evaluate the safety and tolerability of the combined
administration of nilotinib and increasing dose of ruxolitinib in patients with chronic
myeloid leukemia and patients with Philadelphia positive acute lymphoblastic leukemia.